青少年1型糖尿病患者糖尿病技术吸收的差异:全球视角

IF 3 Q2 ENDOCRINOLOGY & METABOLISM Journal of the Endocrine Society Pub Date : 2024-11-28 eCollection Date: 2024-11-26 DOI:10.1210/jendso/bvae210
Rebecca Baqiyyah Conway, Janet Snell-Bergeon, Kyoko Honda-Kohmo, Anil Kumar Peddi, Salbiah Binti Isa, Shakira Sulong, Laurien Sibomana, Andrea Gerard Gonzalez, Jooyoun Song, Kate Elizabeth Lomax, Ching-Nien Lo, Wondong Kim, Aveni Haynes, Martin de Bock, Marie-Anne Burckhardt, Savannah Schwab, Kwanho Hong
{"title":"青少年1型糖尿病患者糖尿病技术吸收的差异:全球视角","authors":"Rebecca Baqiyyah Conway, Janet Snell-Bergeon, Kyoko Honda-Kohmo, Anil Kumar Peddi, Salbiah Binti Isa, Shakira Sulong, Laurien Sibomana, Andrea Gerard Gonzalez, Jooyoun Song, Kate Elizabeth Lomax, Ching-Nien Lo, Wondong Kim, Aveni Haynes, Martin de Bock, Marie-Anne Burckhardt, Savannah Schwab, Kwanho Hong","doi":"10.1210/jendso/bvae210","DOIUrl":null,"url":null,"abstract":"<p><p>Globally, nearly 9 million people are living with type 1 diabetes (T1D). Although the incidence of T1D is not affected by socioeconomic status, the development of complications and limited access to modern therapy is overrepresented in vulnerable populations. Diabetes technology, specifically continuous glucose monitoring and automated insulin delivery systems, are considered the gold standard for management of T1D, yet access to these technologies varies widely across countries and regions, and varies widely even within high-income countries. This review focuses on disparities in diabetes technology use among adolescents and young adults with T1D, barriers to access and use, and summarizes common themes emerging across countries and regions. We conducted a survey among medical technology manufacturers and physicians in various countries across diverse geographical regions and performed extensive literature searches. Across all countries and regions, economic barriers stand out as the largest and most common barriers, either preventing market penetrance of technology into a country or limiting its access to the individual with diabetes due to high out of pocket costs. Other common barriers include structural or accessibility barriers, such as stringent eligibility requirements by insurance providers, regardless of whether the insurance was private or government-based, and provider/individual level barriers. Based on the evidence presented, we suggest the need for a joint effort involving governments, private health insurers, technology manufacturers, and healthcare providers to address the global disparities of diabetic technology utilization and ensure equitable access for all individuals living with T1D worldwide.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"9 1","pages":"bvae210"},"PeriodicalIF":3.0000,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11655873/pdf/","citationCount":"0","resultStr":"{\"title\":\"Disparities in Diabetes Technology Uptake in Youth and Young Adults With Type 1 Diabetes: A Global Perspective.\",\"authors\":\"Rebecca Baqiyyah Conway, Janet Snell-Bergeon, Kyoko Honda-Kohmo, Anil Kumar Peddi, Salbiah Binti Isa, Shakira Sulong, Laurien Sibomana, Andrea Gerard Gonzalez, Jooyoun Song, Kate Elizabeth Lomax, Ching-Nien Lo, Wondong Kim, Aveni Haynes, Martin de Bock, Marie-Anne Burckhardt, Savannah Schwab, Kwanho Hong\",\"doi\":\"10.1210/jendso/bvae210\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Globally, nearly 9 million people are living with type 1 diabetes (T1D). Although the incidence of T1D is not affected by socioeconomic status, the development of complications and limited access to modern therapy is overrepresented in vulnerable populations. Diabetes technology, specifically continuous glucose monitoring and automated insulin delivery systems, are considered the gold standard for management of T1D, yet access to these technologies varies widely across countries and regions, and varies widely even within high-income countries. This review focuses on disparities in diabetes technology use among adolescents and young adults with T1D, barriers to access and use, and summarizes common themes emerging across countries and regions. We conducted a survey among medical technology manufacturers and physicians in various countries across diverse geographical regions and performed extensive literature searches. Across all countries and regions, economic barriers stand out as the largest and most common barriers, either preventing market penetrance of technology into a country or limiting its access to the individual with diabetes due to high out of pocket costs. Other common barriers include structural or accessibility barriers, such as stringent eligibility requirements by insurance providers, regardless of whether the insurance was private or government-based, and provider/individual level barriers. Based on the evidence presented, we suggest the need for a joint effort involving governments, private health insurers, technology manufacturers, and healthcare providers to address the global disparities of diabetic technology utilization and ensure equitable access for all individuals living with T1D worldwide.</p>\",\"PeriodicalId\":17334,\"journal\":{\"name\":\"Journal of the Endocrine Society\",\"volume\":\"9 1\",\"pages\":\"bvae210\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-11-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11655873/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the Endocrine Society\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1210/jendso/bvae210\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/11/26 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Endocrine Society","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1210/jendso/bvae210","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/26 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

全球有近 900 万 1 型糖尿病(T1D)患者。虽然 T1D 的发病率不受社会经济地位的影响,但在弱势群体中,并发症的发生率和获得现代治疗的机会有限的比例过高。糖尿病技术,特别是连续血糖监测和胰岛素自动给药系统,被认为是治疗 T1D 的黄金标准,但这些技术在不同国家和地区的使用情况却大相径庭,即使在高收入国家也是如此。本综述重点关注患有 T1D 的青少年和年轻成人在使用糖尿病技术方面的差异、获得和使用这些技术的障碍,并总结各国和各地区出现的共同主题。我们对不同国家不同地区的医疗技术制造商和医生进行了调查,并进行了广泛的文献检索。在所有国家和地区中,经济障碍是最大也是最常见的障碍,它阻碍了技术在一个国家的市场渗透,或者由于高昂的自付费用而限制了糖尿病患者对技术的使用。其他常见的障碍包括结构性或可及性障碍,如保险提供商的严格资格要求(无论保险是私人的还是政府的),以及提供商/个人层面的障碍。根据所提供的证据,我们建议需要政府、私人医疗保险公司、技术制造商和医疗服务提供商的共同努力,以解决全球糖尿病技术使用方面的差异,并确保全球所有 T1D 患者都能公平地使用这些技术。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Disparities in Diabetes Technology Uptake in Youth and Young Adults With Type 1 Diabetes: A Global Perspective.

Globally, nearly 9 million people are living with type 1 diabetes (T1D). Although the incidence of T1D is not affected by socioeconomic status, the development of complications and limited access to modern therapy is overrepresented in vulnerable populations. Diabetes technology, specifically continuous glucose monitoring and automated insulin delivery systems, are considered the gold standard for management of T1D, yet access to these technologies varies widely across countries and regions, and varies widely even within high-income countries. This review focuses on disparities in diabetes technology use among adolescents and young adults with T1D, barriers to access and use, and summarizes common themes emerging across countries and regions. We conducted a survey among medical technology manufacturers and physicians in various countries across diverse geographical regions and performed extensive literature searches. Across all countries and regions, economic barriers stand out as the largest and most common barriers, either preventing market penetrance of technology into a country or limiting its access to the individual with diabetes due to high out of pocket costs. Other common barriers include structural or accessibility barriers, such as stringent eligibility requirements by insurance providers, regardless of whether the insurance was private or government-based, and provider/individual level barriers. Based on the evidence presented, we suggest the need for a joint effort involving governments, private health insurers, technology manufacturers, and healthcare providers to address the global disparities of diabetic technology utilization and ensure equitable access for all individuals living with T1D worldwide.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of the Endocrine Society
Journal of the Endocrine Society Medicine-Endocrinology, Diabetes and Metabolism
CiteScore
5.50
自引率
0.00%
发文量
2039
审稿时长
9 weeks
期刊最新文献
Lower Cortisol and Dehydroepiandrosterone Sulfate and Higher Food Addiction in Childhood Obesity: Associations With Stress and Dietary Parameters. Testosterone Replacement Therapy and Risk of COVID-19 and Effect of COVID-19 on Testosterone's Treatment Effect. Hypothalamic Estrogen Receptor α Is Essential for Female Marmoset Sexual Behavior Without Protecting From Obesity. Recognition and Management of Ectopic ACTH Secreting Tumors. Predictive Performance of 2 Immunoassays in Patients with Graves Disease Undergoing Radioiodine Therapy: Prospective Study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1